Imaging Scans to Detect Muscle-Invasive Bladder Cancer and Track Pre-Surgery Treatment
Compares FAPI and FDG PET/MRI scans with MRI in adults with muscle-invasive bladder cancer.
Plain-language title generated from the registry record
Registry title: FAPI and FDG PET/MRI in Diagnosis and Therapy Prediction of Bladder Cancer
Key facts
- Where
- Fuzhou, ChinaSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
Source: NCT06421142, who can take part
Where in China
- first hospital affiliated of Fujian medical universityFuzhou, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- First Affiliated Hospital of Fujian Medical University
- Trial code
- NCT06421142
- Record updated
- 1 June 2026
- Original description
The aim of this trial is to investigate the value of FAPI PET/MRI, FDG PET/MRI and MRI in diagnosing MIBC and predicting the efficacy of neoadjuvant therapy for MIBC patients, so as to guide the clinic to adjust the treatment plan in time and benefit MIBC patients.Read full original descriptionShow less
Application Research of FAPI Positron Emission Tomography(PET)/MRI, 18F-Fluorodeoxyglucose (FDG) PET/MRI, and MRI in the Diagnosis of Muscular Invasive Bladder Cancer and Evaluation of Neoadjuvant Therapy Efficacy
The aim of this trial is to investigate the value of FAPI PET/MRI, FDG PET/MRI and MRI in diagnosing MIBC and predicting the efficacy of neoadjuvant therapy for MIBC patients, so as to guide the clinic to adjust the treatment plan in time and benefit MIBC patients.
Inclusion: Inclusion criteria for MIBC diagnostic studies; Patients with suspected muscle-invasive bladder cancer; Completion of FAPI PET/MRI, FDG PET/MRI and MRI; Complete clinical laboratory and pathological data; Inclusion criteria for MIBC neoadjuvant therapy efficacy evaluation study; Patients diagnosed with muscle invasive bladder cancer; Completion of FAPI PET/MRI, FDG PET/MRI, and MRI before neoadjuvant therapy; Complete clinical laboratory and pathological data.
Exclusion: Exclusion criteria for MIBC diagnostic study; Combined with other malignant tumors; Not receiving surgical treatment; Receiving neoadjuvant therapy before surgery; Previous allergy to contrast components or similar components; Serious organ function abnormalities, such as heart, lung, liver, kidney function serious abnormalities; Incomplete clinicopathological data; Exclusion criteria of MIBC neoadjuvant therapy efficacy evaluation study; Combination of other malignant tumors; FAPI PET/MRI, FDG PET/MRI and MRI were not completed after neoadjuvant therapy; Prior hypersensitivity to contrast components or similar components; Serious organ function abnormalities, such as serious abnormalities of heart, lung, liver and kidney function; Incomplete clinicopathological data.